TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analyst consensus is “Hold”: Of 13 analysts covering TransMedics, six rate the stock a buy, six a hold and one a sell. The average 12-month price target is $124.18, versus a recent share price of $86.40.
• Recent analyst views are mixed: Canaccord Genuity and TD Cowen maintained buy ratings, while UBS kept a neutral rating and reduced its target to $77. Needham also cut its target from $142 to $106 despite retaining a buy rating.
• Quarterly results were mixed: Revenue rose 20.7% year over year to $189.95 million, exceeding estimates, but earnings per share of $0.44 missed the $0.50 consensus forecast. The stock is down 2.1%, with shares trading well below their 52-week high of $156.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has been assigned an average recommendation of "Hold" from the thirteen research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $124.1818.

Several equities analysts recently commented on TMDX shares. Canaccord Genuity Group reissued a "buy" rating and issued a $124.00 price objective on shares of TransMedics Group in a research note on Tuesday, June 30th. UBS Group decreased their target price on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. Needham & Company LLC dropped their price target on TransMedics Group from $142.00 to $106.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Finally, TD Cowen reissued a "buy" rating and set a $120.00 price objective on shares of TransMedics Group in a report on Tuesday.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Silvant Capital Management LLC acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $26,000. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group in the 3rd quarter valued at approximately $29,000. North Star Investment Management Corp. bought a new position in shares of TransMedics Group during the first quarter valued at $30,000. Ascentis Independent Advisors bought a new position in shares of TransMedics Group during the first quarter valued at $30,000. Finally, Allworth Financial LP raised its stake in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company's stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Down 2.1%

NASDAQ TMDX opened at $86.40 on Thursday. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The company has a market cap of $2.99 billion, a price-to-earnings ratio of 22.21 and a beta of 1.90. The company has a 50 day moving average of $81.41 and a 200-day moving average of $90.98. TransMedics Group has a 1-year low of $60.10 and a 1-year high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company's quarterly revenue was up 20.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.92 EPS. On average, equities research analysts expect that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.